Sacituzumab govitecan

Drug Profile

Sacituzumab govitecan

Alternative Names: anti-TROP-2-SN-38; Anti-TROP-2-SN-38 conjugate; hRS7-SN 38; hRS7-SN38 antibody drug conjugate; IMMU-132; Isactuzumab govitecan; TROP-2-SN-38

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; Immunomodulators; TROP2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Breast cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Phase II Breast cancer; Solid tumours
  • Preclinical Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 10 Feb 2017 Sacituzumab govitecan licensed to Seattle Genetics worldwide
  • 19 Jan 2017 Safety and efficacy data from a phase I/II trial in Lung cancer released by Immunomedics
  • 19 Jan 2017 Updated efficacy data from a phase II trial in Breast cancer released by Immunomedics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top